-
公开(公告)号：US09273144B2
公开(公告)日：2016-03-01
申请号：US14069445
申请日：2013-11-01
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Hartmut Duefel , Michael Gerg , Frank Kowalewsky , Christian Scholz , Michael Schraeml
CPC classification number: C07K16/22 , C07K14/475 , C07K14/65 , C07K16/1203 , C07K16/40 , C07K2317/34 , C07K2317/565 , C07K2317/92 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/24 , C07K2319/35 , C07K2319/41 , C07K2319/43 , C12N9/90 , C12Y502/01008 , G01N33/573 , G01N33/74 , G01N2333/99
Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.
Abstract translation: 分离的抗体特异性结合包含在人类胰岛素样生长因子-1前体的氨基酸76至氨基酸84的氨基酸区段中的表位（SEQ ID NO：1）。 在一些实施方案中，当存在高过量浓度的胰岛素样生长因子-2（例如在体液样品中）时，使用新型抗体用于敏感和特异性检测胰岛素样生长因子-1。
-
公开(公告)号：US20210061924A1
公开(公告)日：2021-03-04
申请号：US17069349
申请日：2020-10-13
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Hartmut Duefel , Alfred Engel , Frank Kroner , Thomas Meier , Sandra Rutz , Michael Schraeml , Gloria Tabares , Ulrike Kurtkaya , Boris Pinchuk , Christina Zimmermann
IPC: C07K16/40 , G01N33/543
Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1.
-
公开(公告)号：US10197559B2
公开(公告)日：2019-02-05
申请号：US14640263
申请日：2015-03-06
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Hartmut Duefel , Alexander Riedel , Peter Schaarschmidt , Urban Schmitt , Christian Scholz
IPC: C12N9/90 , G01N33/53 , C07K14/245
Abstract: The invention concerns a fusion polypeptide including several molecules of folding helper polypeptides, including one multimerization domain, in particular Skp, and at least one molecule of SlyD or SlpA, wherein no further target polypeptide sequences are fused to the fusion polypeptide. The invention further concerns an immunoassay and the use of the fusion polypeptide in an immunoassay for reduction of interferences or minimizing false positive results or for stabilizing proteinaceous assay reagents. Further the invention concerns a reagent kit for use in an immunoassay comprising the fusion polypeptide.
-
公开(公告)号：US20160137728A1
公开(公告)日：2016-05-19
申请号：US15003988
申请日：2016-01-22
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Hartmut Duefel , Michael Gerg , Frank Kowalewsky , Christian Scholz , Michael Schraeml
IPC: C07K16/22
CPC classification number: C07K16/22 , C07K14/475 , C07K14/65 , C07K16/1203 , C07K16/40 , C07K2317/34 , C07K2317/565 , C07K2317/92 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/24 , C07K2319/35 , C07K2319/41 , C07K2319/43 , C12N9/90 , C12Y502/01008 , G01N33/573 , G01N33/74 , G01N2333/99
Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.
Abstract translation: 分离的抗体特异性结合包含在人类胰岛素样生长因子-1前体的氨基酸76至氨基酸84的氨基酸区段中的表位（SEQ ID NO：1）。 在一些实施方案中，当存在高过量浓度的胰岛素样生长因子-2（例如在体液样品中）时，使用新型抗体用于敏感和特异性检测胰岛素样生长因子-1。
-
公开(公告)号：US11730821B2
公开(公告)日：2023-08-22
申请号：US17933906
申请日：2022-09-21
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Hartmut Duefel , Uwe Kobold , Andreas Leinenbach
CPC classification number: A61K47/68 , G01N33/6848 , G01N2030/8868 , G01N2458/00
Abstract: The present disclosure is directed at an antibody conjugate having an antibody and a tag, wherein one or more element(s) present in the antibody exhibit an isotope ratio which differs from the naturally occurring isotope ratio of the one or more element(s), wherein the amount of the isotope which is less-common in nature, is increased to at least 4% of the atoms of the respective element in the antibody, as well as uses thereof.
-
Patent Agency Ranking
公开(公告)号：US20230022977A1
公开(公告)日：2023-01-26
申请号：US17933906
申请日：2022-09-21
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Hartmut Duefel , Uwe Kobold , Andreas Leinenbach
Abstract: The present disclosure is directed at an antibody conjugate having an antibody and a tag, wherein one or more element(s) present in the antibody exhibit an isotope ratio which differs from the naturally occurring isotope ratio of the one or more element(s), wherein the amount of the isotope which is less-common in nature, is increased to at least 4% of the atoms of the respective element in the antibody, as well as uses thereof.
-
7.发明申请公开(公告)号：US20170261498A1
公开(公告)日：2017-09-14
申请号：US14640263
申请日：2015-03-06
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Hartmut Duefel , Alexander Riedel , Peter Schaarschmidt , Urban Schmitt , Christian Scholz
IPC: G01N33/53 , C07K14/245 , C12N9/90
CPC classification number: G01N33/5306 , C07K14/245 , C07K2319/35 , C07K2319/735 , C12N9/90 , C12Y502/01008
Abstract: The invention concerns a fusion polypeptide comprising several molecules of folding helper polypeptides, comprising one multimerization domain, in particular Skp, and at least one molecule of SlyD or SlpA, wherein no further target polypeptide sequences are fused to said fusion polypeptide. The invention further concerns an immunoassay and the use of said fusion polypeptide in an immunoassay for reduction of interferences or minimizing false positive results or for stabilizing proteinaceous assay reagents. Further the invention concerns a reagent kit for use in an immunoassay comprising said fusion polypeptide.
-
公开(公告)号：US20250043024A1
公开(公告)日：2025-02-06
申请号：US18772484
申请日：2024-07-15
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Hartmut Duefel , Alfred Engel , Frank Kroner , Thomas Meier , Sandra Rutz , Michael Schraeml , Gloria Tabares , Ulrike Kurtkaya , Boris Pinchuk , Christina Zimmermann
IPC: C07K16/40 , G01N33/543
Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1
-
公开(公告)号：US12077600B2
公开(公告)日：2024-09-03
申请号：US17069349
申请日：2020-10-13
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Hartmut Duefel , Alfred Engel , Frank Kroner , Thomas Meier , Sandra Rutz , Michael Schraeml , Gloria Tabares , Ulrike Kurtkaya , Boris Pinchuk , Christina Zimmermann
IPC: G01N31/00 , C07K16/40 , G01N33/53 , G01N33/543
CPC classification number: C07K16/40 , G01N33/54326 , C07K2317/92
Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1.
-
公开(公告)号：US10301383B2
公开(公告)日：2019-05-28
申请号：US15003988
申请日：2016-01-22
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Hartmut Duefel , Michael Gerg , Frank Kowalewsky , Christian Scholz , Michael Schraemi
IPC: C07K16/00 , C07K16/22 , C12N9/90 , C07K16/12 , G01N33/74 , C07K16/40 , G01N33/573 , C07K14/475 , C07K14/65
Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.023 seconds)
